Nuvation Bio
Nuvation Bio is a biopharmaceutical company.
Launch date
Employees
Market cap
€927m
Enterprise valuation
€420m (Public information from Sep 2024)
Share price
$2.95 NUVB
New York City New York (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | 1.4m | <1m | 28.9m |
% growth | - | - | - | - | - | (53 %) | 4282 % |
EBITDA | (43.7m) | (97.3m) | (129m) | (100m) | - | - | - |
Profit | (41.7m) | (86.8m) | (104m) | (75.8m) | (544m) | (150m) | (197m) |
% profit margin | - | - | - | - | (38350 %) | (22781 %) | (681 %) |
EV / revenue | - | - | - | - | 566.0x | 1215.7x | 27.7x |
EV / EBITDA | -4.8x | -19.0x | -3.3x | -3.3x | - | - | - |
R&D budget | 32.6m | 69.0m | 87.8m | 71.3m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$275m | Series A | ||
N/A | N/A | IPO | |
$275m | Post IPO Equity | ||
Total Funding | €250m |
Recent News about Nuvation Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Nuvation Bio
EditACQUISITION by Nuvation Bio Mar 2024